Why the study?
Emerging imaging technologies provide additional information via advanced quantification of biomarkers and improved diagnostic accuracy, motivating a summary of the state of the art and future developments in CMR for ischemic heart disease.
Answers are grounded in this paper and cite their sources.
This review highlights the established diagnostic and prognostic value of CMR in ischemic heart disease and discusses emerging technologies for advanced biomarker quantification.
Ischemic heart disease and its sequelae are one of the major contributors to morbidity and mortality worldwide. Over the last decades, technological developments have strengthened the role of noninvasive imaging for detection, risk stratification, and management of patients with ischemic heart disease. Cardiac magnetic resonance (CMR) imaging incorporates both functional and morphological characterization of the heart to determine presence, acuteness, and severity of ischemic heart disease by evaluating myocardial wall motion and function, the presence and extent of myocardial edema, ischemia, and scarring. Currently established clinical protocols have already demonstrated their diagnostic and prognostic value. Nevertheless, there are emerging imaging technologies that provide additional information based on advanced quantification of imaging biomarkers and improved diagnostic accuracy, therefore potentially allowing reduction or avoidance of contrast and/or stressor agents. The aim of this review is to summarize the current state of the art of CMR imaging for ischemic heart disease and to provide insights into promising future developments.
No takes yet. Share an insight, caveat, or question.
Emrich et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: